Show simple item record

dc.contributor.authorGeorgaki, Maria
dc.contributor.authorAvgoustidis, Dimitris
dc.contributor.authorTheofilou, Vasileios Ionas
dc.contributor.authorPiperi, Evangelia
dc.contributor.authorPettas, Efstathios
dc.contributor.authorKalyvas, Demos G
dc.contributor.authorVlachodimitropoulos, Dimitrios
dc.contributor.authorPerisanidis, Christos
dc.contributor.authorLazaris, Andreas C
dc.contributor.authorNikitakis, Nikolaos G
dc.date.accessioned2021-06-07T17:23:40Z
dc.date.available2021-06-07T17:23:40Z
dc.date.issued2021-05-12
dc.identifier.urihttp://hdl.handle.net/10713/15939
dc.description.abstractOral leukoplakia (OL) has a propensity for recurrence and malignant transformation (MT). Herein, we evaluate sociodemographic, clinical, microscopic and immunohistochemical parameters as predictive factors for OL recurrence, also comparing primary lesions (PLs) with recurrences. Thirty-three patients with OL, completely removed either by excisional biopsy or by laser ablation following incisional biopsy, were studied. Selected molecules associated with the STAT3 oncogenic pathway, including pSTAT3, Bcl-xL, survivin, cyclin D1 and Ki-67, were further analyzed. A total of 135 OL lesions, including 97 PLs and 38 recurrences, were included. Out of 97 PLs, 31 recurred at least once and none of them underwent MT, during a mean follow-up time of 48.3 months. There was no statistically significant difference among the various parameters in recurrent vs. non-recurrent PLs, although recurrence was most frequent in non-homogeneous lesions (p = 0.087) and dysplastic lesions recurred at a higher percentage compared to hyperplastic lesions (34.5% vs. 15.4%). Lower levels of Bcl-xL and survivin were identified as significant risk factors for OL recurrence. Recurrences, although smaller and more frequently homogeneous and non-dysplastic compared to their corresponding PLs, exhibited increased immunohistochemical expression of oncogenic molecules, especially pSTAT3 and Bcl-xL. Our results suggest that parameters associated with recurrence may differ from those that affect the risk of progression to malignancy and support OL management protocols favoring excision and close monitoring of all lesions.en_US
dc.description.urihttps://doi.org/10.3390/diagnostics11050872en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofDiagnostics (Basel, Switzerland)en_US
dc.subjectBcl-xLen_US
dc.subjectKi-67en_US
dc.subjectSTAT3en_US
dc.subjectcyclin D1en_US
dc.subjectlaser ablationen_US
dc.subjectoral leukoplakiaen_US
dc.subjectoral potentially malignant disordersen_US
dc.subjectpredictive biomarkersen_US
dc.subjectrecurrenceen_US
dc.subjectsurvivinen_US
dc.titleRecurrence in Oral Premalignancy: Clinicopathologic and Immunohistochemical Analysisen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/diagnostics11050872
dc.identifier.pmid34066207
dc.source.volume11
dc.source.issue5
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record